Although it is clear that BCR-ABL fusion gene is a key target of imatinib, little else is known about the downstream effects of BCR-ABL or other molecular targets of imatinib in CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.